Bayer's Head of Innovation, Kemal Malik, explains how the revolutionary gene editing technique it invested in will not just treat but cure serious diseases.
David Einhorn's Greenlight Capital returned just 1 percent last quarter, trailing the S&P 500's 6 percent gain.
A repurposed rodent trap might be the best way to control the spread of dangerous, even fatal, tick-borne diseases across the United States.
European markets finished roughly flat on Wednesday, after investors waded through a raft of corporate earnings and news from individual stocks.
“We price our drugs in line with their innovation potential and in line with the competitive environment,” Werner Baumann, CEO of Bayer, told CNBC.
Brian McGee, strategy consultant at Novasecta, takes a look at Bayer's recent earnings while commenting on the firm’s outlook as it continues working with Monsanto.
After meeting with President-elect Donald Trump, Bayer and Monsanto pledged jobs and investment, but is this spending new?
According to Trump's transition team, Bayer will commit to $8 billion in new research and development jobs in the U.S. CNBC's Meg Tirrell reports.
Nearly 70 percent of the world's most innovative companies in 2016 were American, according to a new survey of global executives released on Thursday.
Monsanto CEO Hugh Grant discusses why the Trump administration should approve of Bayer’s takeover of his company.
European stocks closed lower on Wednesday as traders paused for breath after a strong "risk-on" rally since the Donald Trump's election win.
Robert Kindler, Morgan Stanley Vice Chairman and Global Head of M&A, discusses the current environment for mergers and acquisitions as well as what to expect from the likes of the Bayer/Monsanto deal or a potential Saleforce/Twitter deal.
Monsanto reported a surprise adjusted profit, helped by a drop in expenses and higher corn seed volumes.
European stocks closed just above the flatline as investors awaited the outcomes of policy meetings by the U.S. Federal Reserve and Bank of Japan.
U.S. stock-index futures gained on Tuesday as traders awaited the start of the U.S. Federal Reserve's two-day meeting.
Alliance for Bio-Integrity's Steven Druker says the big concern from the merger is the lack of rigorous testing needed for genetically-modified foods.
European stocks ended mostly mixed on Wednesday, as a renewed decline in oil prices put a dampener on sentiment.
Bayer has won over Monsanto with a takeover offer of around $66 billion, ending months of wrangling after increasing its bid for a third time.
Jeremy Redenius, equity analyst for European chemicals at Bernstein, says a merger deal only has a 50 percent chance of getting regulatory approval.
Chemicals group poised to announce deal to buy U.S. seeds company Monsanto for more than $66 billion, people familiar with the matter told Reuters.